1. Home
  2. GXO vs GRFS Comparison

GXO vs GRFS Comparison

Compare GXO & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GXO Logistics Inc.

GXO

GXO Logistics Inc.

HOLD

Current Price

$52.61

Market Cap

5.4B

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$9.27

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GXO
GRFS
Founded
2021
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.2B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
GXO
GRFS
Price
$52.61
$9.27
Analyst Decision
Strong Buy
Hold
Analyst Count
12
2
Target Price
$61.92
$10.15
AVG Volume (30 Days)
1.0M
538.7K
Earning Date
02-11-2026
07-28-2022
Dividend Yield
N/A
1.55%
EPS Growth
N/A
N/A
EPS
0.76
0.64
Revenue
$12,921,000,000.00
$8,821,017,248.00
Revenue This Year
$13.37
$5.36
Revenue Next Year
$6.10
$5.15
P/E Ratio
$69.68
$17.71
Revenue Growth
16.94
7.31
52 Week Low
$30.46
$6.19
52 Week High
$57.99
$11.14

Technical Indicators

Market Signals
Indicator
GXO
GRFS
Relative Strength Index (RSI) 49.83 62.94
Support Level $53.37 $9.04
Resistance Level $54.35 $9.24
Average True Range (ATR) 1.09 0.19
MACD -0.06 0.03
Stochastic Oscillator 26.06 96.21

Price Performance

Historical Comparison
GXO
GRFS

About GXO GXO Logistics Inc.

GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: